11 citations,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
2 citations,
June 2022 in “Molecules” Connarus semidecandrus Jack extract promotes hair growth and thickness, reduces prostate cancer cell growth, and could potentially be used as a treatment for hair loss.
December 2023 in “Research and reports in urology” A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.
18 citations,
July 2015 in “Drug Healthcare and Patient Safety” Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.
129 citations,
February 2006 in “Andrology” Men with low testosterone should be carefully evaluated and monitored before and during treatment.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
September 2010 in “European Urology Supplements” The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
25 citations,
March 2000 in “Journal of Endocrinological Investigation” Testosterone therapy aims to treat hormone deficiencies and various conditions safely and effectively, but requires careful patient monitoring due to potential side effects.
January 2016 in “International Journal of Medical Research and Health Sciences” Baldness (androgenic alopecia) could be a risk factor for prostate cancer.
April 2022 in “Diabetes Therapy” Low testosterone does not prevent prostate cancer in men with type 1 diabetes.
9 citations,
November 2021 in “Infectious Agents and Cancer” Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.
March 2019 in “European Urology Supplements” Some common medications like metformin, insulin, and ACE inhibitors can lower PSA levels, while statins don't, and low dose finasteride significantly reduces PSA.
451 citations,
March 2005 in “Endocrine Reviews” The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.
2 citations,
November 2022 in “Biosensors” A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
1 citations,
February 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Certain interactions help prepare the androgen receptor for pairing and activation, which is important for its role in development and disease.
1 citations,
January 2019 in “PubMed” Baldness score can't be used to predict prostate size.
1 citations,
March 2021 in “F1000Research” Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
26 citations,
March 2006 in “Endocrine, metabolic & immune disorders. Drug targets” This enzyme helps metabolize fatty acids and isoleucine, and could be key in treating neurological diseases and certain cancers.
June 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Six new risk spots for early hair loss were found, which also link to Parkinson's disease and lower fertility. Two genes, FOXA2 and HDAC4, could be new treatment targets. Hair loss might also be connected to heart disease, metabolic syndrome, and prostate cancer.
August 2012 in “Expert Review of Dermatology” Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.
3 citations,
March 2018 in “BMC Cancer” Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.
6 citations,
May 2016 in “Urolithiasis” Balding and low testosterone increase risk of urinary stones.
21 citations,
May 2021 in “Prostate Cancer and Prostatic Diseases” COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
45 citations,
May 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
3 citations,
December 2020 in “Problemy e̊ndokrinologii” Male hormones may make COVID-19 worse, while substances that block these hormones could lessen symptoms.
29 citations,
October 2020 in “eLife” Higher testosterone levels can increase the risk of certain diseases like type 2 diabetes in women and prostate cancer in men, but can also protect against autoimmune diseases and hair loss. It also affects body fat and bone density.
Increased free testosterone can lead to stronger bones and less body fat but also higher risks of prostate cancer, hair loss, spine issues, and high blood pressure.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
Early balding may be a sign of future prostate problems.